Plain-English translation of NCT06843902 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Women living with HIV have a higher risk of heart attacks than women without HIV, partly because their heart arteries don't deliver oxygen-rich blood as well as they should. This study is testing whether medications called SGLT2 inhibitors—already approved for treating diabetes and kidney disease—can improve blood flow through the heart's arteries in women with HIV. The study will compare two groups: one receiving the medication (through a specialist clinic visit) plus health education, and one receiving health education alone.
Currently, many people with HIV who could benefit from this medication aren't receiving it. Researchers want to see whether this treatment can strengthen the heart's blood vessels and reduce heart attack risk in women living with HIV—an area where they may not have enough protection compared to other groups.
You likely qualify if…
You likely don't qualify if…
You'll visit Massachusetts General Hospital for screening tests including blood work and a heart scan (PET/CT) to confirm you qualify. If enrolled, you'll be randomly assigned to either receive health education plus a referral to a specialist clinic (where a doctor may prescribe the medication based on their medical judgment) or health education alone. Both groups will have follow-up visits at 6 months, including repeat blood tests and a heart scan to see if blood flow has improved.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States